---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-330730"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2026-08-03T20:47:12+00:00"
generated_at: "2026-08-03T20:48:08.935999+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma appoints James Ahlers as CFO effective July 30, 2026

## Summary
- James Ahlers appointed CFO of Cue Biopharma effective July 30, 2026.
- Base salary $450,000; eligible for discretionary annual bonus target of 45% of base salary.
- Received inducement option for 51,000 shares at $30.40 and RSU for 25,500 shares, vesting quarterly over 4 years.
- Previously served as CFO of Intarcia Therapeutics, consulting CFO at Danforth Advisors, and roles at Intensity Therapeutics and RenovoRx.
- Severance: 9 months base plus prorated target bonus on qualifying termination; change-in-control triggers full equity acceleration.

## SEC filing metadata
- accession: 0001193125-26-330730
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2026-08-03T20:47:12+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000119312526330730/0001193125-26-330730-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000119312526330730/d134183d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-330730
- JSON: https://secwatch.observer/filing/0001193125-26-330730.json
- Plain text: https://secwatch.observer/filing/0001193125-26-330730.txt

## Key facts
- Executive change
  James Ahlers was appointed as Chief Financial Officer at Cue Biopharma, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On August 3, 2026, Cue Biopharma, Inc. (the “Company”) announced that the Company’s Board of Directors (the “Board”) appointed James Ahlers as the Company’s Chief Financial Officer, effective as of July 30, 2026 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645460/000119312526330730/0001193125-26-330730-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.